Plasminogen concentrate - Kedrion

Drug Profile

Plasminogen concentrate - Kedrion

Alternative Names: Plasminogen - Kedrion

Latest Information Update: 06 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kedrion
  • Class Antithrombotics; Beta-globulins; Blood proteins
  • Mechanism of Action Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type I plasminogen deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Type I plasminogen deficiency

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Feb 2016 Phase-II/III development is ongoing in Italy and USA
  • 30 Dec 2012 Plasminogen concentrate - Kedrion receives Orphan Drug status for Type I plasminogen deficiency in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top